21 CFR § 522.1850 - Polysulfated glycosaminoglycan.

---
identifier: "/us/cfr/t21/s522.1850"
source: "ecfr"
legal_status: "authoritative_unofficial"
title: "21 CFR § 522.1850 - Polysulfated glycosaminoglycan."
title_number: 21
title_name: "Food and Drugs"
section_number: "522.1850"
section_name: "Polysulfated glycosaminoglycan."
chapter_name: "FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES"
subchapter_number: "E"
subchapter_name: "ANIMAL DRUGS, FEEDS, AND RELATED PRODUCTS"
part_number: "522"
part_name: "IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS"
positive_law: false
currency: "2026-04-05"
last_updated: "2026-04-05"
format_version: "1.1.0"
generator: "[email protected]"
authority: "21 U.S.C. 360b."
regulatory_source: "40 FR 13858, Mar. 27, 1975, unless otherwise noted."
cfr_part: "522"
---


# 522.1850 Polysulfated glycosaminoglycan.

(a) *Specifications.* (1) Each 1-milliliter (mL) ampule of solution contains 250 milligrams (mg) polysulfated glycosaminoglycan.

(2) Each mL of solution packaged in 5-mL ampules or 20-, 30-, or 50-mL vials contains 100 mg polysulfated glycosaminoglycan.

(b) *Sponsor.* See No. 010797 in § 510.600(c) of this chapter.

(c) *Special considerations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(d) *Conditions of use*—(1) *Horses*—(i) *Indications for use.* For the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

(ii) *Amount*—(A) *Intra-articular use (carpal)*: 250 mg once a week for 5 weeks.

(B) *Intramuscular use (carpal and hock)*: 500 mg every 4 days for 28 days.

(iii) *Limitations.* Do not use in horses intended for human consumption.

(2) *Dogs*—(i) *Indications for use.* For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

(ii) *Amount.* 2 mg per pound of body weight by intramuscular injection twice weekly for up to 4 weeks (maximum of 8 injections).

[72 FR 56896, Oct. 5, 2007, as amended at 74 FR 67816, Dec. 21, 2009]